News & Events

Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer

Results presented at the ASOPRS 46th Annual Fall Scientific Symposium Friendswood, TX – November 16, 2015 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis. The results also confirmed the technical reliability of the test, which successfully classified 97% of ... Read More

Vast Majority of Ophthalmologists Treating Uveal Melanoma Use Molecular Testing to Guide Patient Care

Castle Biosciences News Release 12/9/14 | Castle Biosciences Inc. today announced the publication of study results that assess current clinical practices for uveal melanoma (UM) and demonstrate the impact of molecular prognostic testing on patient management. The paper, “Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses,” was published in the peer-reviewed journal Clinical Ophthalmology. The publication presents results from three studies: a survey of 109 ophthalmologists specializing in the treatment of uveal melanoma conducted ... Read More

Bascom Palmer Researcher Identifies New Genetic Mutation in Ocular Melanoma

University of Miami Miller School of Medicine, January 24, 2014 | Bascom Palmer Eye Institute ophthalmologist J. William Harbour, M.D., has identified a new genetic marker for determining the virulence of ocular melanomas in a groundbreaking study published online January 13 in the prestigious journal Nature Genetics. “Our research team discovered that the RNA splicing factor SF3B1 is mutated at a very specific location in some ocular melanomas, and this mutation indicates the likelihood that an ocular melanoma will metastasize and spread to other parts of the body, a ... Read More

Enabling Personalized Medicine in the Management of Uveal Melanoma

In the November/December edition of Retina Today, retina specialist Thomas Aaberg Jr. describes the importance of personalized medicine and prognostic testing for patients with uveal melanoma. He explains that recent advances in the field have led to more than 40 active clinical trials testing ways to treat and delay metastatic disease. However, taking advantage of these and future opportunities may require genetic testing of the primary tumor. This presents a significant issue since there is rarely any ... Read More

Castle Biosciences Launches Tissue Repository for Eye Cancer Patients

Patients Undergoing Genetic Test for Uveal Melanoma Will Have Option to Store Remaining Tissue for Future Use Castle Biosciences News Release 9/30/13 – Castle Biosciences Inc. announced today the availability of a tumor tissue repository for patients whose tumors are being tested with the Company’s gene test for uveal, or ocular, melanoma. Patients will now have the option of storing an additional sample of their tumor free of charge for up to five years, and ... Read More

Older Entries »
Know your TYPE, Know your RISK
You’ve just been diagnosed with uveal melanoma, and it’s important to know that there is a test that can identify your tumor type—and the risk of your cancer spreading.

GETTING TESTED       Timing is Critical
To know your tumor type and risk, a biopsy must be taken BEFORE radiation treatment.

Talk to                 Your Doctor
Use this discussion guide to talk to your doctor about the genomic test to learn your tumor type, or CLASS.


Sign Up For Updates

Please leave this field empty.

Share on Facebook+1Share on Twitter

Share Your Stories

There's comfort in knowing you are not alone. If you or a loved one have experienced uveal melanoma and would like to help encourage others whose lives have been touched by this disease, please share your story with us.
Start Sharing